静脉贝利尤单抗治疗儿童系统性红斑狼疮的安全性和有效性:随机安慰剂对照试验结果
这项正在进行的2期随机双盲安慰剂对照研究评估了静脉贝利尤单抗在儿童起病系统性红斑狼疮(cSLE)中的疗效、安全性和药代动力学。第52周时贝利尤单抗组SRI4应答率数值上高于安慰剂组(52.8% vs 43.6%),PRINTO/ACR 30替代定义和PRINTO/ACR 50应答率显著更高,严重不良事件发生率较低,药代动力学与成人研究一致。
要点
- 贝利尤单抗组PRINTO/ACR 30替代定义和PRINTO/ACR 50应答率显著高于安慰剂组。
- SRI4应答率数值上更高但置信区间跨1,研究未针对统计检验设效能。
- 严重不良事件贝利尤单抗组17.0%低于安慰剂组35.0%,安慰剂组发生一例死亡。
核心结论
- 静脉贝利尤单抗在cSLE中的药代动力学和获益-风险特征与成人贝利尤单抗研究一致,10 mg/kg每4周一次剂量是合适的。
研究设计与样本
- 正在进行的2期随机、安慰剂对照、双盲研究,纳入5至17岁儿童起病系统性红斑狼疮患者。
- 患者随机接受贝利尤单抗10 mg/kg静脉注射或安慰剂每4周一次,联合标准SLE治疗。
- 主要终点为第52周SLE应答指数(SRI4)应答率;研究未针对统计检验设效能。
主要发现
- 第52周SRI4应答率贝利尤单抗组52.8% vs 安慰剂组43.6%,OR 1.49(95% CI 0.64至3.46)。
- PRINTO/ACR 30替代定义应答率贝利尤单抗组52.8% vs 安慰剂组27.5%,OR 2.92(95% CI 1.19至7.17)。
- PRINTO/ACR 50应答率贝利尤单抗组60.4% vs 安慰剂组35.0%,OR 2.74(95% CI 1.15至6.54)。
- SRI4持续应答(第44至52周)贝利尤单抗组43.4% vs 安慰剂组41.0%,OR 1.08(95% CI 0.46至2.52)。
- Parent-global持续应答贝利尤单抗组59.1% vs 安慰剂组33.3%,OR 3.49(95% CI 1.23至9.91)。
关键数值与推荐
- 严重不良事件发生率贝利尤单抗组17.0%,安慰剂组35.0%;安慰剂组发生一例死亡。
- 第52周贝利尤单抗谷浓度几何均值56.2 µg/mL(95% CI 45.2至69.8)。
- PRINTO/ACR 30替代定义和PRINTO/ACR 50应答率贝利尤单抗组均高于安慰剂组,OR分别为2.92(95% CI 1.19至7.17)和2.74(95% CI 1.15至6.54)。
临床怎么用
- 对于5至17岁儿童起病系统性红斑狼疮患者,静脉贝利尤单抗10 mg/kg每4周一次联合标准治疗可作为考虑选项。
- 贝利尤单抗在cSLE中的药代动力学与成人研究一致,支持按体重10 mg/kg每4周一次给药。
局限性
- 研究未针对统计检验设效能,SRI4主要终点组间差异置信区间跨1。
- 样本量较小(贝利尤单抗组53例,安慰剂组40例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This ongoing Phase-2, randomised, placebo-controlled, double-blind study evaluated the efficacy, safety and pharmacokinetics of intravenous belimumab in childhood-onset systemic lupus erythematosus (cSLE). METHODS: Patients (5 to 17 years) were randomised to belimumab 10 mg/kg intravenous or placebo every 4 weeks, plus standard SLE therapy. Primary endpoint: SLE Responder Index (SRI4) response rate (Week 52). Key major secondary endpoints: proportion of patients achieving the Paediatric Rheumatology International Trials Organisation/American College of Rheumatology (PRINTO/ACR) response using 50 and '30 alternative' definitions (Week 52), and sustained response (Weeks 44 to 52) by SRI4 and Parent Global Assessment of well-being (Parent-global). Safety and pharmacokinetics were assessed. Study not powered for statistical testing. RESULTS: Ninety-three patients were randomised (belimumab, n=53; placebo, n=40). At Week 52, there were numerically more SRI4 responders with belimumab versus placebo (52.8% vs 43.6%; OR 1.49 (95% CI 0.64 to 3.46)). PRINTO/ACR 30 alternative (52.8% vs 27.5%; OR 2.92 (95% CI 1.19 to 7.17)) and PRINTO/ACR 50 (60.4% vs 35.0%; OR 2.74 (95% CI 1.15 to 6.54)) responses were more frequent with belimumab than placebo, as were sustained responses for SRI4 (belimumab, 43.4%; placebo, 41.0%; OR 1.08 (95% CI 0.46 to 2.52)) and Parent-global (belimumab, 59.1%; placebo, 33.3%; OR 3.49 (95% CI 1.23 to 9.91)). Serious adverse events were reported in 17.0% of belimumab patients and 35.0% of placebo patients; one death occurred (placebo). Week-52, geometric mean (95% CI) belimumab trough concentration was 56.2 (45.2 to 69.8) µg/mL. CONCLUSION: The belimumab intravenous pharmacokinetics and benefit-risk profile in cSLE are consistent with adult belimumab studies and the 10 mg/kg every 4 weeks dose is appropriate. TRIAL REGISTRATION NUMBER: NCT01649765.
引用
- Brunner HI, Abud-Mendoza C, Viola DO, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020. PMID: 32699034. doi:10.1136/annrheumdis-2020-217101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。